It Seems Altimmune, Inc. (ALT) Will Go Down. Just Reaches 52 Week Low

April 17, 2018 - By Peter Erickson

The stock of Altimmune, Inc. (NASDAQ:ALT) hit a new 52-week low and has $0.73 target or 7.00 % below today’s $0.79 share price. The 6 months bearish chart indicates high risk for the $14.31 million company. The 1-year low was reported on Apr, 17 by If the $0.73 price target is reached, the company will be worth $1.00 million less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock.

The stock decreased 5.48% or $0.0458 during the last trading session, reaching $0.7902. About 300,412 shares traded or 9.37% up from the average. Altimmune, Inc. (NASDAQ:ALT) has declined 84.57% since April 17, 2017 and is downtrending. It has underperformed by 96.12% the S&P500.

Altimmune, Inc., a clinical stage immunotherapeutic biotechnology company, creates and develops immunotherapeutic products for treating acute respiratory infections, chronic viral infections, and cancer. The company has market cap of $14.31 million. The firm develops NasoVAX, an intranasally administered recombinant influenza vaccine that has completed Phase I clinical trials; and HepTcell, an immunotherapy for patients chronically infected with the hepatitis B virus, which is in Phase I clinical trials. It currently has negative earnings. The Company’s preclinical stage products include NasoShield, a vaccine for the prevention of anthrax disease following inhalation of pathogen spores; and Oncosyn, an immunotherapeutic for treating solid cancer indications, such as lung, colorectal, melanoma, breast, ovarian, and others.

Altimmune, Inc. (NASDAQ:ALT) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: